Sirico Marianna, D'Angelo Alberto, Gianni Caterina, Casadei Chiara, Merloni Filippo, De Giorgi Ugo
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
Department of Life Sciences, University of Bath, Bath BA2 7AY, UK.
Cancers (Basel). 2023 Jan 23;15(3):703. doi: 10.3390/cancers15030703.
The phosphoinositide 3 kinase (PI3K)-protein kinase B (PKB/AKT)-mammalian target of the rapamycin (mTOR) axis is a key signal transduction system that links oncogenes and multiple receptor classes which are involved in many essential cellular functions. Aberrant PI3K signalling is one of the most commonly mutated pathways in cancer. Consequently, more than 40 compounds targeting key components of this signalling network have been tested in clinical trials among various types of cancer. As the oncogenic activation of the PI3K/AKT/mTOR pathway often occurs alongside mutations in other signalling networks, combination therapy should be considered. In this review, we highlight recent advances in the knowledge of the PI3K pathway and discuss the current state and future challenges of targeting this pathway in clinical practice.
磷脂酰肌醇3激酶（PI3K）-蛋白激酶B（PKB/AKT）-雷帕霉素哺乳动物靶蛋白（mTOR）轴是一个关键的信号转导系统，它连接着癌基因和多种受体类型，这些受体参与许多重要的细胞功能。PI3K信号异常是癌症中最常见的突变途径之一。因此，超过40种针对该信号网络关键成分的化合物已在各类癌症的临床试验中进行了测试。由于PI3K/AKT/mTOR途径的致癌激活通常与其他信号网络的突变同时发生，因此应考虑联合治疗。在这篇综述中，我们重点介绍了PI3K途径知识的最新进展，并讨论了在临床实践中靶向该途径的现状和未来挑战。
